You are here

Dr. Shelly Krebs, Chief of B Cell Biology

Monoclonal antibodies (mAbs) have a long history in the treatment of chronic diseases and are rapidly becoming an important countermeasure for the SARS-CoV-2 pandemic. Individuals who recovered from COVID-19 likely mounted an immune response that helped them recover. By isolating mAbs from these individuals, the Krebs lab is trying to identify key components of their immune response that can be used to help others who don’t mount a protective response to defeat the virus.

Under leadership from WRAIR’s Emerging Infectious Diseases Branch (EIDB), the Krebs lab is working on ways to use mAbs to help

  • prevent COVID infection in the absence of a vaccine
  • diagnose the disease as part of immunoassay development
  • develop treatment options that could blunt disease severity

Dr. Krebs received her Ph.D. from Dartmouth Medical School in 2008 in the department of Microbiology and Immunology. She transitioned to studying HIV when she was awarded an Emerging Infectious Disease Postdoctoral Fellowship from the CDC and APHL, focusing on low-cost diagnostics and the development of a whole-inactivated HIV vaccine. She joined HJF and MHRP in 2012 to study the development of HIV-specific B cell responses and immune activation in HIV infection and vaccination.